Trial
NCT04789837
The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Sadat City University
Collaborators
—
Condition
Osteoarthritis
Intervention
Cilostazol 50 MG
Why stopped
Institutional and funding constrains
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-14